HistoSonics, an Ann Arbor, Mich.- and Minneapolis, MN-based developer of a non-invasive robotics platform and novel beam therapy, closed a $54m Series C financing.
The round was led by Varian Medical Systems, Inc., with participation from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Lumira Ventures, Venture Investors, the State of Wisconsin Investment Board, existing investors, and Fred Moll, MD. In conjunction with the funding, Greg Sorensen, Vice President of Strategy and Business Development at Varian, joined HistoSonics’ Board of Directors, along with Gerry Brunk, Managing Director of Lumira Ventures, and an appointee from JJDC.
The company plans to use the funds to complete key regulatory and commercial milestones and expand development of its platform.
Led by President and CEO Mike Blue, HistoSonics provides a non-invasive platform, Robotically Assisted Sonic Therapy (RASTSM), which combines advanced robotics and imaging with proprietary sensing technology to deliver personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures enough to liquify and destroy targeted tissues at sub-cellular levels.